National Minority Quality Forum to Launch the National Clinical Trial Network With Microsoft

mia.burns February 14, 2013–The National Minority Quality Forum announced today a collaboration between its National Health Index (NHI) and Microsoft Corporation to launch the ...

What happens to the FDA in a government shutdown?

Damian Garde With hope for congressional compromise waning by the hour, the federal government is bracing for its first shutdown in 17 years, and for the FDA, that means furloughing ...

Lilly fails to persuade Medicare to pay for Alzheimer’s imaging drug

Tracy Staton The Centers for Medicare & Medicaid Services has handed down its final decision on Eli Lilly's Alzheimer's imaging agent Amyvid. The final answer, after appeals ...

EMA Accepts AstraZeneca’s Naloxegol Application

mia.burns Marketing Authorisation Application for naloxegol accepted by European Medicines Agency Friday, 27 September 2013 AstraZeneca today announced that the European Medicines ...

Dainippon Submits Antipsychotic Approval Application in China

mia.burns Dainippon Sumitomo Pharma submits an application for an atypical antipsychotic blonanserin (Brand name in Japan: LONASEN®) in China Osaka, Japan, September 27, 2013 – ...

Forget The Apology: Japan To Raid Novartis Offices Over Diovan Scandal

esilverman Japanese authorities plan to raid Novartis offices after a health ministry panel concluded that the drugmaker should be held responsible for using falsified research ...

Third Rock’s path to success lined with patience, rigor and T-shirts

Damian Garde Looking at this year's boom in high-dollar biotech IPOs, you can't miss the fingerprints of Third Rock Ventures, with three of the hottest market debuts coming ...

Principal unmet needs still outstanding for Alzheimer’s patients

mia.burns By Mia Burns (mia.burns@ubm.com) In the world of treating mild to moderate Alzheimer’s disease, the drugs offering a greater effect on cognition and function compared with ...

Are side effects warnings good for sales? In TV ads, yes

Tracy Staton This is either a story about the virtues of honesty or the ever-changing minds of the American consumer. That litany of drug side-effects that's delivered rapid-fire ...

‘Our Commercial Model Is Focused On The Right Things:’ Glaxo’s Rawcliffe Explains

esilverman The last year has proved quite interesting and, in many ways, quite crucial for GlaxoSmithKline. The drugmaker is counting on a spate of new products to win approval ...

If ex-Intermune CEO’s conviction goes to the Supreme Court, who wins?

Tracy Staton Does free speech apply to pharma marketing? Last year, a U.S. appeals court ruled that it does–and that sales reps and drugmakers that tout drugs for off-label use ...

Ex-Amgen CEO to would-be leaders: Focus on behavior, not abilities

Tracy Staton If you could bring in former Amgen CEO Kevin Sharer as a consultant, what would he say? FiercePharma News
Page 30 of 204« First...1020...2829303132...405060...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS